Kyverna Therapeutics, Inc.
KYTX · NASDAQ
Market closed$7.45$0.010000 (+0.13%)After hours $7.50 · +0.67%
Key statistics
Previous close$7.44
Open$7.26
Day high$7.68
Day low$7.20
52-week high$13.67
52-week low$2.80
Market cap326.25M
Volume872.89K
Average volume1.21M
P/E ratio-2.27
Forward P/E—
EPS-3.28
Dividend yield0.00%
Market context
Why it moved
KYTX edged slightly higher amid routine trading activity, with no significant company-specific news identified as a clear catalyst for today's modest price movement.
What is happening
Recent company-specific developments and publisher coverage.
24/7 Wall St. · July 10, 2026Kyverna Therapeutics Sinks 13%: Here’s WhySeeking Alpha · July 6, 2026Kyverna Therapeutics: The Autoimmune CAR T Beachhead Is Bigger Than SPS (KYTX)Stock Titan · June 22, 2026Kyverna adds legal chief as it prepares for commercializationQuiver Quantitative · May 18, 2026Kyverna Therapeutics Appoints Greg Martini as Chief Financial Officer | KYTX Stock NewsStock Titan · May 14, 2026Watch Kyverna discuss autoimmune cell therapies at two live webcastsThe Clinical Trial Vanguard · May 13, 2026Kyverna’s SPS CAR-T Therapy Advances to BLA Based on Natural History Study DataInvesting.com · April 23, 2026H.C. Wainwright reiterates Kyverna Therapeutics stock rating at buyQuiver Quantitative · April 21, 2026Kyverna Therapeutics Reports Positive Trial Results for Miv-cel in Stiff Person Syndrome, Highlighting Potential to Transform Treatment Paradigm Benzinga · June 3, 2026Kyverna Therapeutics Reports Phase 1 Data For Miv-Cel In Rheumatoid Arthritis, Showing Deep B-Cell Depletion And Potential Immune Reset At Week 36 Mt Newswire · May 18, 2026Kyverna Therapeutics Names Greg Martini CFO Benzinga · May 13, 2026JP Morgan Maintains Overweight on Kyverna Therapeutics, Lowers Price Target to $29 Benzinga · May 12, 2026Kyverna Therapeutics Q1 EPS $(0.66) Beats $(0.73) Estimate Benzinga · April 22, 2026Reported Earlier, Kyverna's Miv-Cel Meets All Primary And Secondary Endpoints In KYSA-8 Registrational Trial, Potentially First Approved Treatment For Stiff Person Syndrome Benzinga · April 22, 2026Kyverna Therapeutics (KYTX) Stock Surges 24% After Hours: Why Is It Moving? Benzinga · April 2, 2026Kyverna Therapeutics Enters Open Market Sale Agreement With Jefferies Dated March 27, 2025; Co. May Offer Up To $100M Of Common Stock Mt Newswire · March 26, 2026Kyverna Therapeutics Files $300 Million Mixed Shelf